The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer - The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer

ICI and AA therapy had significantly higher ORR than either monotherapy. PFS and OS were favorable benefits in ICI and AA therapy; however, significant heterogeneity was identified in these analyses. According to the administration timing and sequence, ICI immediately after AA showed no PFS and OS benefits compared to ICI monotherapy, whereas favorable PFS and OS were demonstrated when AA was concomitantly administered with ICI or when AA was administered immediately after ICI.